Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Mortality risk after clinical management of recurrent and metastatic adenoid cystic carcinoma
by
Wu, Tara J.
, Xu, Melody J.
, van Zante, Annemieke
, Algazi, Alain P.
, Ha, Patrick K.
, Yom, Sue S.
, El-Sayed, Ivan H.
, Ryan, William R.
in
Adenoid cystic carcinoma
/ Cancer metastasis
/ Carcinoma
/ Head and Neck Surgery
/ Health aspects
/ Lung metastases
/ Medical research
/ Medicine
/ Medicine & Public Health
/ Mortality
/ Oral and Maxillofacial Surgery
/ Original
/ Original Research Article
/ Otorhinolaryngology
/ Plastic Surgery
/ Recurrence
/ Recurrence (Disease)
/ Skull base
/ Survival
2018
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Mortality risk after clinical management of recurrent and metastatic adenoid cystic carcinoma
by
Wu, Tara J.
, Xu, Melody J.
, van Zante, Annemieke
, Algazi, Alain P.
, Ha, Patrick K.
, Yom, Sue S.
, El-Sayed, Ivan H.
, Ryan, William R.
in
Adenoid cystic carcinoma
/ Cancer metastasis
/ Carcinoma
/ Head and Neck Surgery
/ Health aspects
/ Lung metastases
/ Medical research
/ Medicine
/ Medicine & Public Health
/ Mortality
/ Oral and Maxillofacial Surgery
/ Original
/ Original Research Article
/ Otorhinolaryngology
/ Plastic Surgery
/ Recurrence
/ Recurrence (Disease)
/ Skull base
/ Survival
2018
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Mortality risk after clinical management of recurrent and metastatic adenoid cystic carcinoma
by
Wu, Tara J.
, Xu, Melody J.
, van Zante, Annemieke
, Algazi, Alain P.
, Ha, Patrick K.
, Yom, Sue S.
, El-Sayed, Ivan H.
, Ryan, William R.
in
Adenoid cystic carcinoma
/ Cancer metastasis
/ Carcinoma
/ Head and Neck Surgery
/ Health aspects
/ Lung metastases
/ Medical research
/ Medicine
/ Medicine & Public Health
/ Mortality
/ Oral and Maxillofacial Surgery
/ Original
/ Original Research Article
/ Otorhinolaryngology
/ Plastic Surgery
/ Recurrence
/ Recurrence (Disease)
/ Skull base
/ Survival
2018
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Mortality risk after clinical management of recurrent and metastatic adenoid cystic carcinoma
Journal Article
Mortality risk after clinical management of recurrent and metastatic adenoid cystic carcinoma
2018
Request Book From Autostore
and Choose the Collection Method
Overview
Background
Management of locoregional recurrence (LRR) and distant metastasis (DM) in adenoid cystic carcinoma (ACC) is guided by limited data. We investigated mortality risks in patients diagnosed and treated for recurrent ACC.
Methods
A retrospective review of ACC patients treated from 1989 to 2016 identified 36 patients with LRR or DM. High-risk disease was defined as skull base involvement (for LRR) or International Registry of Lung Metastases Group III/IV or extrapulmonary site of metastasis (for DM). Kaplan-Meier method, log-rank tests, and Cox proportional hazards were used for time-to-event analysis.
Results
Among 20 LRR and 16 DM patients, the median times to recurrence were 51 and 50 months, respectively. The median follow-up post-recurrence was 37.5 months (interquartile range (IQR)16.5–56.5). Post-recurrence 3-year overall survival (OS) was 78.5%, 73.3% for LRR and 85.1% for DM (
p
= 0.62). High-risk recurrences were associated with worse 3-year OS (68.8% for high-risk and 92.3% for low-risk, χ2 = 10.4,
p
= 0.001).
Among LRR patients, 90% had surgery as part of their treatment. Multimodality therapy, age, and histopathologic features (size, margins, solid histology, lymphovascular or perineural invasion) were not associated with PFS or OS. High-risk LRR was the only variable associated with OS (χ2 = 5.9,
p
= 0.01).
Among DM patients, six were initially managed with observation and ten received surgery, RT, or systemic therapy. Upfront therapy was not associated with improved PFS or OS. High-risk DM was the only variable associated with OS (χ2 = 4.7,
p
= 0.03).
Conclusions
High-risk LRR and DM were associated with decreased 3-year OS. More effective therapies are needed for high-risk ACC recurrences.
Publisher
BioMed Central,BioMed Central Ltd,SAGE Publishing
Subject
This website uses cookies to ensure you get the best experience on our website.